Aducanumab: European agency reȷects Alzheimer’s drug over efficacy and safety concerns
The European Medicines Agency (EMA) has recommended the refusal of a marketing authorisation for Alzheimer’s disease drug aducanumab (Aduhelm) because of a lack of evidence that it will work and…
